Figure 4.

(A–D) Mutated allele frequencies, tumor marker CA19-9 levels and tumor load according to RECIST 1.1 for exemplary patients spanning the respective therapy line from baseline before therapy initiation to disease progression; BL = baseline, SD = stable disease, PD = progressive disease.